Because the vitamin deposits into muscle rather than entering the vasculature immediately, intramuscular delivery produces a sustained release effect
preclinical safety evaluation found no genotoxicity, mutagenicity, or organ toxicity at tested doses
Mechanistic Comparison# Dosing Comparison# Amycretin Dosing# Amycretin dosing is investigational: Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1 Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks Phase 3 dose selection will be informed by the completed phase 2 data
FOXO4-DRI Safety and Side Effects: What the Evidence Shows (2026) In the published mouse studies, FOXO4-DRI caused no reported side effects: treated animals kept their weight, blood counts, and organ markers while senescent cells were cleared, and the peptide spared healthy cells in culture
Persistent pain after replacement what's going on and how PT helps.
Inject subcutaneously